In this light, the overexpression of TROP2 has not been definitively correlated with improved therapeutic responses in patients with advanced NSCLC who have undergone anti-TROP2 ADC treatment [20]. This evidence concerns the gene TACSTD2 and non-small cell lung carcinoma.